Youssef et al. showed that elevated plasma levels of IL-18 may be an important independent predictor of adverse clinical events within 30 days in ST-elevation myocardial infarction (STEMI) patients [36]. The gene discussed is IL18; the disease is ST Elevation Myocardial Infarction.